PMC:7204657 / 1760-1982 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"67","span":{"begin":189,"end":207},"obj":"Gene"},{"id":"68","span":{"begin":209,"end":212},"obj":"Gene"},{"id":"72","span":{"begin":79,"end":90},"obj":"Chemical"}],"attributes":[{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"Gene:1401"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"Gene:1401"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"MESH:C502936"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"clinicians should be aware of the potential for this adverse event. Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevatio"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T13","span":{"begin":128,"end":138},"obj":"Body_part"},{"id":"T14","span":{"begin":200,"end":207},"obj":"Body_part"}],"attributes":[{"id":"A13","pred":"fma_id","subj":"T13","obj":"http://purl.org/sig/ont/fma/fma7199"},{"id":"A14","pred":"fma_id","subj":"T14","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"clinicians should be aware of the potential for this adverse event. Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevatio"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T19","span":{"begin":128,"end":150},"obj":"Disease"}],"attributes":[{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0006807"}],"text":"clinicians should be aware of the potential for this adverse event. Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevatio"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T24","span":{"begin":128,"end":138},"obj":"http://purl.obolibrary.org/obo/UBERON_0000160"},{"id":"T25","span":{"begin":128,"end":138},"obj":"http://www.ebi.ac.uk/efo/EFO_0000834"}],"text":"clinicians should be aware of the potential for this adverse event. Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevatio"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T10","span":{"begin":79,"end":90},"obj":"Chemical"},{"id":"T11","span":{"begin":200,"end":207},"obj":"Chemical"}],"attributes":[{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A11","pred":"chebi_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"clinicians should be aware of the potential for this adverse event. Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevatio"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T3","span":{"begin":106,"end":126},"obj":"http://purl.obolibrary.org/obo/GO_0006953"}],"text":"clinicians should be aware of the potential for this adverse event. Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevatio"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T9","span":{"begin":106,"end":126},"obj":"Phenotype"},{"id":"T10","span":{"begin":128,"end":150},"obj":"Phenotype"}],"attributes":[{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0033331"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0031368"}],"text":"clinicians should be aware of the potential for this adverse event. Lastly, as tocilizumab attenuates the acute phase response, intestinal perforation may not necessarily cause significant C-reactive protein (CRP) elevatio"}